Physician

Cristine Radojicic, MD

According to 2025 Medicare claims, Cristine Radojicic, MD (NPI: 1245294206) practices allergy/immunology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is DUKE HEALTH INTEGRATED PRACTICE, INC. (NPI: 1205553369; TIN: 862109896) and primary practice location at 27713-8505. Radojicic is affiliated with the Duke Connected Care, LLC (ACO ID: A2419), participating under the MSSP model.

Radojicic's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 174 traditional Medicare patients, billed 2,384 HCPCS/CPT codes, and received $33,720 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,127 prescription claims across 201 beneficiaries totaling $2,047,867 in drug costs, led by Takhzyro (Lanadelumab-Flyo). DME data shows 33 claims. Open Payments data shows 64 records totaling $79,152. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $9,925 and ending at $33,720. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,149,231 to $2,047,867. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,883 to $413.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	116	144	$9,925
2016	138	317	$11,691
2017	284	6,045	$83,157
2018	301	4,757	$71,403
2019	295	3,979	$64,484
2020	214	2,492	$33,903
2021	220	3,168	$55,157
2022	220	2,772	$42,492
2023	198	2,850	$42,751
2024	174	2,384	$33,720

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	139	866	$1,149,231
2016	132	867	$1,072,210
2017	183	651	$406,211
2018	184	995	$923,525
2019	198	1,014	$975,293
2020	181	1,016	$1,310,210
2021	191	1,102	$1,701,138
2022	179	1,070	$1,539,382
2023	200	1,147	$2,197,761
2024	201	1,127	$2,047,867

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	139	$245,323
2016	N/R	110	$301,968
2017	N/R	85	$121,904
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	31	$1,640
2021	N/R	13	$954
2022	N/R	51	$2,374
2023	N/R	54	$9,807
2024	N/R	33	$881

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	63	63	$159
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	26	28	$129
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	67	86	$84
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	78	98	$12
95004	Test for allergy using allergenic extract	36	1,747	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Takhzyro	Lanadelumab-Flyo	21	588	$1,072,528
Dupixent Pen	Dupilumab	64	1,764	$255,793
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	68	2,040	$43,392
Breo Ellipta	Fluticasone/Vilanterol	70	3,060	$38,433
Epinephrine	Epinephrine	69	846	$15,464

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	16	$519
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	17	$362

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	64	$79,152	CSL Behring
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Cristine Radojicic, MD?

Tedicare shows public-source Medicare data for Cristine Radojicic, MD (NPI 1245294206), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Cristine Radojicic, MD have ACO affiliation data?

Cristine Radojicic, MD is shown with ACO affiliation data for Duke Connected Care, LLC (MSSP, ACO ID A2419).

What billing organization is linked to Cristine Radojicic, MD?

Cristine Radojicic, MD is linked to DUKE HEALTH INTEGRATED PRACTICE, INC. (billing NPI 1205553369) in the available physician profile data.

Does Cristine Radojicic, MD have Open Payments data?

Cristine Radojicic, MD has 64 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.